With the 2027 college entrance exam just one day away, the number of teenagers prescribed methylphenidate — an ADHD medication widely known as a "study drug" — has nearly tripled over the past five years, data showed Wednesday.
Prescriptions among teenagers peaked in August, during the summer break, and were concentrated in areas known for intense academic competition, including Seoul's Gangnam-gu and Songpa-gu and Seongnam's Bundang-gu in Gyeonggi Province.
The Health Insurance Review and Assessment Service analyzed national health insurance claims data from 2021 to 2025 and found that the number of patients aged 15 to 19 prescribed methylphenidate jumped 177.6 percent — from 20,955 in 2021 to 58,174 last year, according to Yonhap.
Methylphenidate is used to treat attention deficit hyperactivity disorder (ADHD) but is colloquially referred to as the "college entrance exam drug" or "focus drug." It is also illegally sold and brokered online.
Over the same period, the total number of national health insurance claims for the drug rose 2.6 times, from 170,984 to 440,641, while the total dosage dispensed increased 2.7 times, from about 5.95 million units to 16.24 million units.
The seasonal prescription index for methylphenidate among teenagers exceeded 100 from April through October and fell below 100 from November through March.
The seasonal prescription index is a measure designed to filter out the overall year-on-year trend in prescription volume and capture monthly seasonal variation. A reading above 100 means prescriptions in that month were higher than usual; below 100 means they were lower.
By month, the teenage seasonal prescription index peaked in August — with readings of 104.3 for patient count, 106.1 for claims and 107.9 for total dosage — and hit its lowest point in December, at 90.8, 92.6 and 89.0, respectively.
By contrast, the index for all age groups remained above 100 even in November and December.
Unlike the broader population, teenagers' methylphenidate prescriptions decline at the end and start of the year — a pattern that points to a drop-off after the college entrance exam is administered.
By region, Seoul accounted for 29.8 percent of teenage methylphenidate claims last year, followed by Gyeonggi Province at 25.4 percent and Busan at 10.9 percent. Together, these three regions accounted for 66 percent of all claims nationwide.
At the district level, the top five areas by claims in 2025 were Gangnam-gu in Seoul (25,992 claims), Songpa-gu in Seoul (17,001), Bundang-gu in Seongnam, Gyeonggi Province (16,356), Seocho-gu in Seoul (12,583) and Suseong-gu in Daegu (12,299). All five are known for high academic intensity, and the same districts ranked in the top five by patient count and total dosage as well.
Prescriptions of propranolol — a beta-blocker mistakenly known among some students as an "anti-tremor drug" — also rose among teenagers.
The number of patients aged 15 to 19 prescribed propranolol increased 1.5 times, from 48,255 in 2021 to 70,507 in 2025, while claims over the same period rose 1.4 times, from 214,044 to 303,616.
The monthly seasonal claims index for propranolol also peaked in October, the month before the college entrance exam, at 120.1, and was lowest in February at 69.5.
husn7@heraldcorp.com
